| Nov 15 |
Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations
|
| Nov 14 |
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
|
| Nov 13 |
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
|
| Nov 12 |
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss
|
| Nov 12 |
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
|
| Oct 24 |
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
|
| Oct 23 |
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
|
| Oct 9 |
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
|
| Sep 25 |
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
|
| Sep 4 |
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
|
